Director, FDA Oncology Center of Excellence
Appears in 1 story
Led the FDA review that granted accelerated approval
The Food and Drug Administration approved AstraZeneca's pill Etcamah (camizestrant) on September 4, 2026, for people with metastatic breast cancer whose tumors carry an estrogen receptor-1 (ESR1) mutation. It is the first cancer therapy approved based on a resistance mutation found in blood before scans show the disease has progressed.
Updated 3 days ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
